SCHEMBL581736

SCHEMBL581736

Fc1ncc(Cl)c(Cl)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10620493 0.79
SCHEMBL338632 0.79
SCHEMBL30661614 0.79
SCHEMBL9682588 0.75
SCHEMBL10768918 0.75
SCHEMBL9682583 0.75
SCHEMBL20844096 0.75
SCHEMBL29372810 0.72
SCHEMBL155314 0.72
SCHEMBL10952404 0.72 RPS6KA5 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10792282-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2020-10-06 US disclosed
EP-3296309-B1 GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS UNIV GENT (BE) 2019-08-07 EP disclosed
US-10005777-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2018-06-26 US disclosed
EP-2970275-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2018-05-09 EP disclosed
EP-3296309-A1 GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS Universiteit Gent (BE) 2018-03-21 EP disclosed
US-20180030050-A1 Protein Kinase C Inhibitors and Uses Thereof MIDCAP FINANCIAL TRUST 2018-02-01 US disclosed
US-20170360786-A1 Protein Kinase C Inhibitors and Uses Thereof RIGEL PHARMACEUTICALS, INC. 2017-12-21 US disclosed
EP-2833889-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2017-11-01 EP disclosed
EP-2877480-B1 GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS UNIV GENT (BE) 2017-09-06 EP disclosed
US-9682976-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2017-06-20 US disclosed
WO-2007087276-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2007-08-02 WO disclosed
EP-1185505-B1 METHOD OF PRODUCING METHOXYIMINO ACETIC AMIDE BAYER CROPSCIENCE AG (DE) 2004-11-03 EP disclosed
US-6660872-B1 In high yields BAYER AKTIENGESELLSCHAFT (DE) 2003-12-09 US disclosed
EP-1185505-A1 METHOD OF PRODUCING METHOXYIMINO ACETIC AMIDE Bayer Aktiengesellschaft (DE) 2002-03-13 EP disclosed
WO-2000071504-A1 METHOD OF PRODUCING METHOXYIMINO ACETIC AMIDE BAYER AKTIENGESELLSCHAFT (DE) 2000-11-30 WO disclosed
US-5882356-A Fibre treatment COURTAULDS FIBRES (HOLDINGS) LIMITED (GB) 1999-03-16 US disclosed
EP-0665904-B1 FIBRE TREATMENT COURTAULDS FIBRES HOLDINGS LTD (GB) 1998-11-18 EP disclosed
EP-0665904-A1 FIBRE TREATMENT COURTAULDS FIBRES (HOLDINGS) LIMITED (GB) 1995-08-09 EP disclosed
WO-1994009191-A1 FIBRE TREATMENT COURTAULDS FIBRES (HOLDINGS) LIMITED (GB) 1994-04-28 WO disclosed
EP-0016931-A2 Reactive azo dyestuffs, their use in dyeing and printing materials containing amide or hydroxyl groups BAYER AG (DE) 1980-10-15 EP disclosed